WESTLAKE VILLAGE, Calif., Jan. 18, 2005 (PRIMEZONE) -- Addison-Davis Diagnostics, Inc. (OTCBB:ADDI) is pleased to announce that it has secured the City of Yonkers, New York as a customer for Patent Pending DrugStop Addison-Davis' rapid-test for drugs of abuse. Yonkers is the 4th largest city in the State of New York, located in Westchester County and just north of New York City. With its Drug Stop product, Addison-Davis addresses the problem of drug abuse in the workplace, with the goal of assisting Federal, State and local municipalities with this dilemma.
Addison-Davis CEO Edward Withrow comment's, "The City of Yonkers account is an important penetration into a targeted major market for Addison-Davis. Our goal, consistent with the national mandate for a drug free environment, is to provide municipalities across the United States with our DrugStop product."
About DrugStop:
A completely self-contained and self-regulating, on-site drug testing product that uses a rapid immunoassay for the qualitative detection of drug metabolites in urine. DrugStop eliminates specimen exposure, reduces the chances of complications in handling, and is the only test available that does not require processing once the sample is collected. DrugStop is designed for human resource professionals for testing a number of different types of drugs including amphetamines, cocaine, opiates, phencyclidine, and cannabinoids.
About Addison-Davis:
Addison-Davis is currently focused on developing fast and reliable "Point-of-Care" Diagnostic Testing through the use of its patented technology to Healthcare Professionals, Hospitals, Minor Emergency Centers, Ambulance, Para-Medics and all branches of the Government. This innovative technology is suitable for the most common and time sensitive medical conditions and diseases. ADDI has licensed the patents to proven Point-of-Care quick-test devices and analyzers that easily evolve and adapt to the rapidly changing professional and governmental healthcare market. Many of these innovative devices are already Food and Drug Administration ("FDA") 510(k) cleared. For more information about Addison-Davis Diagnostics, Inc. visit: http://www.addisondavis.com
To hear an audio interview with Edward Withrow, CEO of ADDI, please visit: www.macreport.net
This press release contains forward-looking statements that involve risks, uncertainties and assumptions that if they never materialize or prove incorrect, could cause the results of Addison-Davis Diagnostics, Inc. to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any projections of earnings, revenue, or other financial items, any statements of the plans, strategies, and objectives of management for future operations, any statements concerning proposed new products, services or developments, any statements regarding future economic conditions or performance, statements of belief and any statements of assumptions underlying any of the foregoing. These statements are based on expectations as of the date of this press release. Actual results may differ materially from those projected because of a number of risks and uncertainties, including those detailed from time to time in the reports filed by Addison-Davis Diagnostics, Inc. with the Securities and Exchange Commission. Addison-Davis Diagnostics, Inc. assumes no obligation and does not intend to update these forward-looking statements.
For further information contact: